Nancy Lurker
CIK 1450485 · Executive Vice Chair · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.06M
Companies
8
Total Filings
101
Lifetime Open-Market Net
-$2.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 18,222 | $48.37 | $881.4K | $0 | 7 | 2026-05-22 |
| COLL | Director | 26,758 | $29.11 | $778.9K | -$161.9K | 4 | 2026-05-18 |
| EYPT | Director | 421,235 | $12.83 | $5.40M | -$1.46M | 44 | 2026-01-07 |
| AQST | Director | — | $3.92 | — | $0 | 4 | 2021-06-17 |
| EyePoint, Inc. (PSDV) Delisted | President & CEO | 95,033 | — | — | $100.0K | 4 | 2018-03-21 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 10,507 | $0.34 | $3.6K | $0 | 4 | 2016-03-18 |
| INTERPACE BIOSCIENCES, INC. (PDII) Delisted | CEO | 477,317 | — | — | $235.8K | 13 | 2015-03-09 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | -$1.10M | 10 | 2015-01-30 |
Recent Filings · Page 8 of 11
101 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-21 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | +38,333 | $0 | EDGAR |
| 2017-12-19 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-14 | EyePoint, Inc. (PSDV) Delisted | Buy (P) | +56,700 | $100.0K | EDGAR |
| 2016-12-14 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-18 | Keenova Therapeutics plc (MNK) Delisted | Mixed | +3,583 | -$25.5K | EDGAR |
| 2015-03-23 | Keenova Therapeutics plc (MNK) Delisted | Grant (A) | +1,715 | $0 | EDGAR |
| 2015-03-09 | INTERPACE BIOSCIENCES, INC. (PDII) Delisted | Grant (A) | +444,364 | $768.7K | EDGAR |
| 2015-01-30 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Other (J) | −10,000 | -$365.3K | EDGAR |
| 2014-12-08 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Mixed | −7,430 | -$611.0K | EDGAR |
| 2014-11-12 | INTERPACE BIOSCIENCES, INC. (PDII) Delisted | Buy (P) | +49,000 | $85.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.